Floatz logo

Cediranib

Cutaneous B-cell Non-Hodgkin Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Cutaneous B-cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
University of Chicago
Phase 2BBB
Fludarabine
Case Comprehensive Cancer Center
Phase 2BBB
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Wake Forest University Health Sciences
Phase 2BBB
DEXAMETHASONE
University of Chicago
Phase 2BBB

View all 50 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →